SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 9.99% Stake in Danimer Scientific

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, disclosing a shared beneficial ownership of 9.99% of Danimer Scientific, Inc.'s Class A Common stock as of March 31, 2025.

Summary

• Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in Danimer Scientific, Inc.
• As of March 31, 2025, the Reporting Persons collectively beneficially own 89,999 shares of Danimer Scientific, Inc.'s Class A Common stock.
• This represents 9.99% of the Class A Common stock outstanding.
• Armistice Capital, LLC, as the investment manager of Armistice Capital Master Fund Ltd., exercises voting and investment power over these securities.
• Steven Boyd, as the managing member of Armistice Capital, is deemed to beneficially own these securities.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 240.14a-11.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain qualitative statements that would indicate positive or negative sentiment regarding the issuer's performance or outlook.

Positives

• The disclosure indicates a significant investment interest in Danimer Scientific, Inc. by Armistice Capital, LLC and Steven Boyd, holding a 9.99% stake.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Armistice Capital Master Fund Ltd., a Cayman Islands exempted company, is the direct holder of the shares and is an investment advisory client of Armistice Capital, LLC, one of the reporting persons.

Stakeholder Impact

• Shareholders are impacted by the disclosure of a significant ownership stake, as it identifies a major investor (Armistice Capital, LLC and Steven Boyd) holding 9.99% of the Class A Common stock.

Key Dates

Keywords

Danimer Scientific, Armistice Capital, Steven Boyd, Schedule 13G, beneficial ownership, Class A Common stock, SEC filing, investment management